Quick Answer
BriaCell Therapeutics Corp. reported R&D Expense of $21.27 million for fiscal year 2025.
BriaCell Therapeutics Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $21.27M | -21.7% |
| 2024 | $27.18M | +77.2% |
| 2023 | $15.34M | +91.2% |
| 2022 | $8.02M | +296.9% |
| 2021 | $2.02M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $6.68M | +82.3% | +38.9% |
| April 30, 2025 | $4.81M | -37.2% | -15.4% |
| January 31, 2025 | $5.68M | -31.2% | +55.1% |
| October 31, 2024 | $3.67M | -46.5% | -52.1% |
| April 30, 2024 | $7.66M | +98.4% | -7.3% |
| January 31, 2024 | $8.26M | +170.4% | +20.4% |
| October 31, 2023 | $6.86M | +110.7% | +77.6% |
| April 30, 2023 | $3.86M | +70.2% | +26.4% |
- BriaCell Therapeutics Corp. showed a decrease of -21.7% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, BriaCell Therapeutics Corp.’s r&d expense has grown by 952.5% (from $2.02 million to $21.27 million).
- The most recent figure is from BriaCell Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on October 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: